Sun Yun

Recipient of the first National Outstanding Physician Award, the first National Medical Master Craftsman Award, Shanghai Craftsman, Shanghai Leading Talent, and recipient of the State Council Special Government Allowance. Chairman of the Reproductive Medicine Branch of the Shanghai Medical Association, Director of the Shanghai Human Assisted Reproductive Technology Quality Control Center. Doctor of Medicine, Chief Physician, Dr., Doctoral Supervisor. Clinical Director of the Reproductive Medicine Center at Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Deputy Director of the Shanghai Key Laboratory of Assisted Reproduction and Eugenics. The project he led, "Innovation and Promotion of Key Technologies for Precision Diagnosis and Treatment of Implantation Disorders," won the second prize of the 2025 National Science and Technology Progress Award. This research addresses three major clinical challenges in assisted reproduction: poor seed quality, poor soil quality, and difficult implantation. It pioneered a non-invasive detection technology that can screen healthy embryos with minimal waste cells or culture medium, reducing damage to the embryo caused by biopsy. By mapping the endometrial molecular spectrum over time, the accuracy of implantation window diagnosis is improved to the hourly level, enabling precise correction of implantation window deviation in patients. As one of the main promoters of the single embryo transfer strategy in China, the clinical application of this approach has reduced the multiple pregnancy rate by 60%, significantly lowered the risk of premature birth, safeguarded the bottom line of maternal and infant safety, and driven global standard reform. In 2023, DR. Chen Zijiang and Dr. Sun Yun led a team that published groundbreaking research results in the top international medical journal JAMA, pointing out that oral prednisone does not improve the live birth rate of assisted reproductive technology, overturning clinical empirical treatment and helping hundreds of thousands of pregnant women avoid unnecessary hormone exposure each year. This achievement was recognized as one of the top ten clinical medical advances in "Important Medical Advances in China in 2023". In the past five years, he has presided over 15 projects, including the National Key Research and Development Program (Chief Scientist), and published more than 100 SCI papers as the first or corresponding author in journals such as NEJM, Lancet, JAMA, and PNAS. As the first author, he has won the second prize of the National Science and Technology Progress Award, the first prize of the Chinese Medical Science and Technology Award, and the first prize of the Shanghai Science and Technology Progress Award. He has been selected as one of the top 2% of scientists in the world.